SQZ Biotechnologies

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ cell therapy platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

Earnings data Q3 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Cantor Global Healthcare Conference on September 29. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings. PRESENTATION DETAILS Wednesday, September 29 Cantor Global Healthcare Conference Corporate Overvi

SQZ Biotechnologies to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the company's Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. The company anticipates an IND filing in the third quarter of 2022. In preclin

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at Citi's 16th Annual Virtual Biopharma Conference on September 10, and at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings at b

SQZ Biotechnologies to Present at Upcoming Health Care Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial results and recent portfolio updates. “This was an exciting quarter for the company as we reported first-in-human data at ASCO for our investigational APC cell therapy, which demonstrated an encouraging safety profile, rapid SQZ manufacturing and early signs of immune activity,” said Armon Share

SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial and clinical development expertise. “We are thrilled to have Bernard and Patrick join our Board,” said Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies. “As we execute o

SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenerative medicine data showing that the company's Cell Squeeze® technology can be used to generate neurons from induced human pluripotent stem cells (iPSCs) through the single delivery of an mRNA encoding fate-specifying transcription factor. The new findings build upon recent clinical and pre-clinic

SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

SQZ Biotechnologies Company (NYSE: SQZ) has announced preclinical results from its Tolerizing Antigen Carrier (TAC) program, showing potential for application in various autoimmune diseases. Data will be presented at the 2021 Federation of Clinical Immunology Sciences annual meeting.

SQZ Biotechnologies' TAC Program Induces Multiple Mechanisms Of Antigen-Specific Tolerance, Animal Study Shows

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results from the company's Tolerizing Antigen Carrier (TAC) program demonstrating that its engineered TACs can drive antigen-specific immune tolerance through key mechanisms relevant to many complex autoimmune diseases. In models of Type 1 diabetes (T1D), SQZ™ TACs were able to delete antigen-specific T ce

SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic Human Papillomavirus positive (HPV16+) tumors. The trial also showed that the compa

SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. Armon Sharei, PhD, chief executive officer, will present a corporate overview on June 2 at 3:00 pm EDT with a virtual webcast and host one on one meetings. More information about and access to the webcast for th

SQZ Biotech to Present at Jefferies Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manufacturing, and antitumor activity data from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV-101 in patients with advanced or metastatic Human Papillomavirus Positive tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8. “These early data demonstr

SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the period ended March 31, 2021 and reviewed recent business highlights. “We continue to execute across our broad and differentiated cell therapy pipeline and are excited by the potential patient impact of these programs to treat cancer, autoimmune, and infectious diseases,” said Armon Sharei, Ph.D., C

SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the BofA (Bank of America) Securities 2021 Virtual Health Care Conference taking place May 11-13, 2021. Armon Sharei, PhD, chief executive officer, will present a corporate overview on May 12 at 8:00am EDT with a virtual webcast and the company will be hosting one on one meetings. More infor

SQZ Biotech to Present at BofA Securities 2021 Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced today that it will present new data on the company's scaled cGMP cell therapy manufacturing program at the 2021 American Society for Gene and Cell Therapy Virtual Annual Meeting (ASGCT) from May 11-14. The company will also present findings on the performance advantages of cells engineered through its proprietary Cell Squeeze® Technolog

SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its next generation SQZ™ APCs, enhanced APCs or eAPCs, and the potentially broader applicability of the platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting. “One of the advantages of the Cell Squeeze® technology is the ability to simultaneously engineer multiple functions in cells

SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in multiple investor conferences in April 2021. Armon Sharei, PhD, chief executive officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021 and will participate in a cell therapy focused panel at the Canaccord Horizons in

SQZ Biotech to Participate in April Investor Events

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights. “In 2020, we experienced the most important moment in SQZ's journey so far: dosing our first patient. This accomplishment was coupled with exciting progress across our pipeline and the transition to being a public company. Despite the many challenges of COVID-19, our

SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next generation SQZ™ APCs and the broader applicability of the APC platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually April 10-15, 2021. SQZ APC is a cell therapy platform that aims to induce powerful antigen specific CD8+ T cell r

SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting

SQZ Biotechnologies Company (SQZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy SQZ Biotechnologies Company (SQZ) Ahead of Earnings?

SQZ Biotechnologies is a cell therapy manufacturing company developing its own pipeline of medicines. The investment thesis is centered around a large market opportunity to treat HPV+ solid tumors and the margin of safety provided by SQZ's sizable partnership with Roche.

SQZ Biotechnologies: Cell Therapy Manufacturing Platform

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, will present a corporate overview at the upcoming virtual H.C. Wainwright Global Life Sciences Conference. The presentation will be available through the virtual conference portal on Tuesday, March 9, 2021 at 7:00 am EST. The team is also taking individual meetings at the eve

SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference

The cell-squeezing specialist priced a new stock issue.

Why SQZ Biotechnologies Sank on Friday

SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.

SQZ Biotechnologies Under Pressure After $60M Equity Raise At 9% Discount

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenced an underwritten public offering of 3,000,000 shares of common stock. All of the shares of common stock are being offered by SQZ. In addition, SQZ expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, l

SQZ Biotech Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that the company's Investigational New Drug (IND) application for SQZTM Activating Antigen Carriers (SQZ AACs) in HPV+ tumors was cleared by the U.S. Food and Drug Administration (FDA). The clinical trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells (RBCs) engineered with tumor-specific ant

SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors

News for SQZ Biotechnologies Stock (SQZ)